Peptomyc announces first patient dosed in Phase 2 clinical trial of OMO-103 in advanced osteosarcoma11 / 03 / 25|
Peptomyc announces the beginning of a Phase 2 clinical trial of OMO-103 in advanced osteosarcoma16 / 01 / 25|
Peptomyc announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC patients09 / 12 / 24|
Peptomyc S.L. Expands its Patent Portfolio with a Patent Grant in Hong Kong for its Methods and Composition for the Treatment of Cancer19 / 08 / 24|
Peptomyc S.L. Expands Patent Portfolio with European and Indian Patent Grant for its Methods and Composition for the Treatment of Cancer15 / 07 / 24|
Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial06 / 02 / 24|
The spin-off Peptomyc and VHIO awarded €4 million from the Spanish Ministry of Science and Innovation to advance the clinical development of the first direct MYC inhibitor20 / 12 / 23|
Peptomyc announces first patient dosed in Phase Ib trial of OMO-103 in combination with standard of care chemotherapy in first-line metastatic PDAC patients28 / 11 / 23|
Peptomyc is awarded €5 million from the Horizon Europe EIC Accelerator Program to conduct a Phase 1b clinical trial with OMO-103 in patients and scale up its manufacturing process31 / 10 / 23|
